Skip to main content
main-content
Top

15-12-2021 | Anti-VEGF agents | Adis Journal Club | Article

Targeted Oncology

MYL-1402O: A Bevacizumab Biosimilar

share
SHARE
print
PRINT
insite
SEARCH

Authors: Arnold Lee

Abstract

MYL-1402O (Abevmy®, Lextemy®) is a biosimilar of the reference anti-vascular endothelial growth factor antibody bevacizumab. Abevmy® is approved for use in all indications for which reference bevacizumab is approved, including the treatment of non-small cell lung cancer (NSCLC) and other solid cancers. Lextemy® is approved for all indications as reference bevacizumab, except in recurrent ovarian cancer. MYL-1402O has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab, and the pharmacokinetic similarity of the agents has been shown in healthy male subjects. MYL-1402O demonstrated clinical efficacy equivalent to that of reference bevacizumab in patients with non-squamous NSCLC. The tolerability, safety and immunogenicity profiles of MYL-1402O were consistent with those of reference bevacizumab. The role of reference bevacizumab in the management of solid cancers is well established and MYL-1402O provides an effective biosimilar alternative for patients requiring bevacizumab therapy.

View the full open access article

MYL-1402O: Key Points

Biosimilar to reference bevacizumab.

Equivalent efficacy and tolerability to reference bevacizumab in patients with stage IV non-squamous NSCLC.

Similar pharmacokinetic and pharmacodynamic properties to those of reference bevacizumab.

MYL-1402O (as Abevmy®) is approved for all indications for which reference bevacizumab is approved.

share
SHARE
print
PRINT